P86.11 A Real-World Feasibility Study of Patients with Solid Tumors Harboring NRG1 Gene Fusions: NSCLC Subset Analysis

Durable responses to afatinib have been achieved in patients with solid tumors harboring NRG1 gene fusions, including NSCLC, in case reports. Key objectives of this feasibility assessment were to determine the number of patients with NRG1 gene fusion-positive solid tumors available for analyses, characterize their treatment with afatinib/other systemic therapies, and gain insights into treatment patterns and testing for a larger, retrospective, real-world data study. Here, we report a subgroup analysis of patients with NSCLC, the most common primary diagnosis in this feasibility assessment.